0001410939-23-000080.txt : 20230519
0001410939-23-000080.hdr.sgml : 20230519
20230519174759
ACCESSION NUMBER: 0001410939-23-000080
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230517
FILED AS OF DATE: 20230519
DATE AS OF CHANGE: 20230519
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Blumenkranz Mark S.
CENTRAL INDEX KEY: 0001614869
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36080
FILM NUMBER: 23941748
MAIL ADDRESS:
STREET 1: C/O 1LIFE HEALTHCARE, INC.
STREET 2: ONE EMBARCADERO CENTER, SUITE 1900
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94111
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IVERIC bio, Inc.
CENTRAL INDEX KEY: 0001410939
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 208185347
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8 SYLVAN WAY
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
BUSINESS PHONE: (609) 474-6755
MAIL ADDRESS:
STREET 1: 8 SYLVAN WAY
CITY: PARSIPPANY
STATE: NJ
ZIP: 07054
FORMER COMPANY:
FORMER CONFORMED NAME: Ophthotech Corp.
DATE OF NAME CHANGE: 20070828
4
1
wk-form4_1684532862.xml
FORM 4
X0407
4
2023-05-17
0
0001410939
IVERIC bio, Inc.
ISEE
0001614869
Blumenkranz Mark S.
C/O IVERIC BIO, INC.
8 SYLVAN WAY
PARSIPPANY
NJ
07054
1
0
0
0
0
Restricted Stock Units
2023-05-17
4
A
0
7500
0
A
Common Stock
7500
7500
D
Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the units.
Subject to the Reporting Person providing continued services to the Registrant and other terms and conditions under the Registrant's 2023 Stock Incentive Plan, the award of restricted stock units will vest in full on the earlier of one business day prior to the Registrant's 2024 annual meeting of stockholders or the first anniversary of the grant date. Any unvested shares subject to the award of restricted stock units will be accelerated in full upon the occurrence of a change in control event (as defined in the Registrant's 2023 Stock Incentive Plan). For purposes of this report on Form 4, a change in control event includes the closing of the transaction contemplated by the Agreement and Plan of Merger, dated April 28, 2023, between the Registrant, Astellas US Holding, Inc., Berry Merger Sub, Inc. and solely as provided by Section 8.10(b) of such agreement, Astellas Pharma Inc.
/s/ Todd D.C. Anderman, as Attorney-in-Fact for Mark S. Blumenkranz
2023-05-19